Therapy for atopic dermatitis is multi-faceted and encompasses ... should be avoided in areas of thinner skin, including the eyelids, face, mucous membranes, genitalia, and intertriginous areas ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD) that is not well controlled, despite treatment with topical prescription therapies.

The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and ...

Atopic dermatitis, or eczema ... Among the common side effects of EBGLYSS were eye and eyelid inflammation, including redness, swelling and itching. Some also experience injection site reactions ...